Abstract
Abstract:
Respiratory Syncytial Virus (RSV) is a highly contagious pathogen causing significant respiratory infections across all age groups, with heightened severity in infants and the elderly. This paper provides a comprehensive overview of the virus's epidemiology, the associated dangers, and current therapeutic interventions. Historical data identifies RSV as a primary cause of respiratory hospitalizations in infants and ageing populations, with reinfection common throughout life. After several trials and molecular diagnostics to find treatment options, various vaccines, antiviral drugs, and monoclonal antibodies have been licensed for use in various parts of the world. Recent studies explore the importance of passive immunization and propose various antiviral approaches targeting the RSV fusion protein and replication mechanisms. Observational research indicates that limiting sibling visitation in neonatal intensive care units (NICUs) significantly reduces RSV transmission. Additionally, the disease burden in infants and young children is exacerbated by congenital conditions such as Down syndrome and pulmonary hypertension, leading to higher morbidity and mortality rates. Although the existing treatment options have helped in reducing the severity of Respiratory Syncytial Virus (RSV) infections, particularly in vulnerable populations like infants, the elderly, and immunocompromised individuals, more research needs to be done by relevant experts with the aim of finding a cure for RSV.
Acknowledgements
We would like to thank Christine A. Hamilton, DHSc, RRT, FAARC, Nebraska Methodist College, Omaha Nebraska for editing first draft of this research. Also, we are very grateful for Tennessee State University and University of San Diego where we graduated from, which helped us a lot to come out with this manuscript.
Recommended Citation
Alshammari TA, Alqahtani AM. Respiratory Syncytial Virus. The Internet Journal of Allied Health Sciences and Practice. 2025 Jul 28;23(3), Article 20.
